News and features

Monte Rosa Therapeutics, a company originally formed as a spinout from Cancer Research UK-funded drug discovery research at the ICR, in collaboration with Versant’s drug discovery engine Ridgeline Therapeutics, has closed a $96m ‘series B’ financing from investors to support the further development of its drug pipeline.

Lara Jukes is the Director of Development at the ICR. Here she shares her personal thoughts on the impact the coronavirus pandemic has had on the charity, the life-saving research it supports, and those who benefit from it.

Researchers at the ICR are working hard to improve the outlook for children with cancer. Here we look back on a decade of discoveries made possible by the support of the parent-led charity Christopher’s Smile, which was founded just over 10 years ago.

An experimental cancer drug used alongside targeted hormone treatment could treat an aggressive group of prostate cancers which have become ‘addicted’ to growth signals, a major phase III clinical trial has shown.

A new treatment for breast cancer patients with hormone receptor (HR+) early stage disease who are at a high risk of recurrence has been shown to reduce the risk by 25 per cent in the first two years, according to a new study.

A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Almost half of patients who received a targeted drug during treatment for newly diagnosed BRCA-mutated advanced ovarian cancer remain disease free after five years, according to a study led by The Royal Marsden NHS Foundation Trust.

Professor Louis Chesler is Head of the new Centre for Paediatric Experimental Medicine at the ICR – and leads an ambitious team of researchers who are investigating new targeted treatments that could make a real difference for children with cancer.

Launching a dual-pronged attack on tumours using a combination of two innovative precision medicines could treat patients with multiple common cancers, a new clinical trial shows.

Researchers have created a mathematical model that can determine the impact of the immune system on tumour evolution.

A blood test that can identify a variety of mutations in advanced breast cancer can reliably match women to effective targeted treatments, early results of a major clinical trial reveal.

The ICR has welcomed the approval by the Scottish Medicines Consortium (SMC) of the immunotherapy, pembrolizumab, as a first-line NHS treatment for some patients with head and neck cancer.